Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
28 studies found for:    Ox40
Show Display Options
Rank Status Study
1 Withdrawn Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Anti-OX40;   Drug: Ipilimumab
2 Completed A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
Condition: Asthma
Interventions: Drug: huMAb OX40L;   Drug: placebo
3 Recruiting Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
Conditions: Metastatic Breast Cancer;   Lung Metastases;   Liver Metastases
Intervention: Biological: MEDI6469
4 Recruiting Anti-OX40 Antibody in Head and Neck Cancer Patients
Condition: Head and Neck Cancer
Interventions: Drug: Anti-OX40 antibody administration;   Procedure: Surgical Resection
5 Active, not recruiting Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer
Condition: Advanced Cancer.
Interventions: Drug: Cohort 1 anti-OX40;   Drug: Cohort 2 anti-OX40;   Drug: Cohort 3 anti-OX40;   Biological: Tetanus Day 29;   Biological: Tetanus Day 1;   Biological: KLH Day 1;   Biological: KLH Day 29
6 Active, not recruiting Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Conditions: Metastatic Prostate Cancer;   Cancer of the Prostate;   Prostate Cancer
Interventions: Drug: Anti-OX40;   Radiation: Radiation;   Drug: Cyclophosphamide
7 Withdrawn Study of Immune Responses in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Intervention: Biological: anti-OX40
8 Recruiting Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: MEDI6469
9 Completed OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Condition: Cancer
Interventions: Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
10 Recruiting Vasculopathy, Inflammation and Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Biological: Blood samples;   Biological: Biopsy
11 Recruiting Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Condition: Neoplasms
Interventions: Drug: PF-04518600;   Drug: PF-04518600 plus PF-05082566
12 Not yet recruiting 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: Fludarabine;   Genetic: GINAKIT Cells
13 Recruiting Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
Conditions: Ulcerative Colitis;   Digestive System Diseases;   Colitis, Ulcerative;   Colitis;   Gastrointestinal Diseases;   Inflammatory Bowel Diseases;   Intestinal Diseases;   Colonic Diseases;   Autoimmune Disease;   Abdominal Pain
Interventions: Drug: KHK4083;   Drug: Placebo
14 Recruiting Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
Condition: Rabies
Intervention: Biological: rabies vaccine
15 Unknown  Omegaven (w-3 Fish Oil) Supplemented Parenteral Nutrition in Subjects of SICU.
Condition: Critical Ill Patients in SICU
Intervention: Drug: Omegaven 10%
16 Active, not recruiting A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Condition: Recurrent or Metastatic Solid Tumors
Interventions: Biological: MEDI6383;   Biological: MEDI6383 and MEDI4736
17 Recruiting A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Biological: MEDI0562
18 Recruiting A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Conditions: Sarcoma;   Osteosarcoma;   Neuroblastoma;   Melanoma
Interventions: Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide
19 Active, not recruiting 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Condition: Neuroblastoma
Interventions: Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells;   Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: pembrolizumab
20 Completed Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
Condition: Glomerulonephritis, IGA
Intervention: Procedure: gene transcription and cytometry

   Previous Page Studies Shown (1-20) Next Page (21-28) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.